clinical 668 words KG: ent-clin-f5ca1b71 2026-03-29
kind:clinical-trialsection:clinical-trialsstate:publishedtopic:dravet-syndrometopic:scn1atopic:gene-therapytopic:neurodevelopmental-epilepsy
Contents

Roche/Neurocrine SCN1A AAV Gene Therapy — Dravet Syndrome

Knowledge Graph

Related Hypotheses (21)

Bacterial Enzyme-Mediated Dopamine Precursor Synthesis
Score: 0.36
Gamma entrainment therapy to restore hippocampal-cortical sy
Score: 0.68
Selective Acid Sphingomyelinase Modulation Therapy
Score: 0.65
CYP46A1 Overexpression Gene Therapy
Score: 0.63
PARP1 Inhibition Therapy
Score: 0.58

Related Analyses (19)

CRISPR-based therapeutic approaches for neurodegenerative di
neurodegeneration · archived
CRISPR-based therapeutic approaches for neurodegenerative di
neurodegeneration · completed
What delivery mechanisms can achieve therapeutically relevan
drug delivery · failed
TDP-43 phase separation therapeutics for ALS-FTD
neurodegeneration · archived
APOE4 structural biology and therapeutic targeting strategie
neurodegeneration · archived

Related Experiments (6)

AAV Serotype Comparison for LRRK2 Knockdown in PD Gene Thera
validation · proposed · Score: 0.40
AAV-LRRK2 IND-Enabling Study Design
clinical · proposed · Score: 0.40
AAV Serotype Comparison for LRRK2 Knockdown in PD
validation · proposed · Score: 0.40
ER-Golgi Secretory Pathway Dysfunction in PD - Experiment De
clinical · proposed · Score: 0.40
Gene Therapy: AAV Serotype Comparison for LRRK2 Knockdown
validation · proposed · Score: 0.40